ArticleCase reports in obstetrics and gynecology2022

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.

Maya Gross et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.